The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies.

The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies.
复制标题

DOI:
10.1038/s41590-020-0728-z
复制
发表时间:
2020-08
期刊:
影响因子:
30.5
通讯作者:
Barry KC
Barry KC
中科院分区:
医学1区
文献类型:
--
作者:
Bald T;Krummel MF;Smyth MJ;Barry KC

文献摘要

参考文献

被引文献

相似文献

自然杀伤(NK)细胞属于先天免疫系统,通过杀死受感染的、外来的、应激的或转化的细胞来部分保护宿主。此外,通过细胞串扰,NK细胞协调抗肿瘤免疫应答。因此,已经进行了大量的努力来开发NK细胞在癌症中的治疗特性。临床前和临床开发中的当前策略包括过继转移疗法、直接刺激、将NK细胞募集到肿瘤微环境(TME)中、限制NK细胞功能的抑制性受体的阻断和TME的治疗性调节以增强抗肿瘤NK细胞功能。在这篇综述中,我们介绍了NK细胞-癌症周期,突出NK细胞生物学的最新进展,并讨论了基于NK细胞的癌症免疫治疗的进展和问题。
Natural Killer (NK) cells belong to the innate immune system and in part protect the host through killing of infected, foreign, stressed or transformed cells. Additionally, via cellular cross-talk, NK cells orchestrate anti-tumor immune responses. Hence, significant efforts have been undertaken to exploit the therapeutic properties of NK cells in cancer. Current strategies in preclinical and clinical development include adoptive transfer therapies, direct stimulation, recruitment of NK cells into the tumor microenvironment (TME), the blockade of inhibitory receptors that limit NK cell functions and therapeutic modulation of the TME to enhance anti-tumor NK cell function. In this review, we introduce the NK cell-cancer cycle to highlight recent advances in NK cell biology and discuss the progress and problems of NK cell-based cancer immunotherapies.
DOI: 10.1016/j.jim.2017.03.009
发表时间: 2018-03
影响因子: 2.2
作者:
Bengsch B;Ohtani T;Herati RS;Bovenschen N;Chang KM;Wherry EJ
通讯作者: Wherry EJ
DOI: 10.1182/blood-2012-06-438028
发表时间: 2012-11-22
期刊: BLOOD
影响因子: 20.3
作者:
Benson, Don M., Jr.;Hofmeister, Craig C.;Farag, Sherif S.
通讯作者: Farag, Sherif S.
DOI: 10.1101/cshperspect.a028480
发表时间: 2019-03-01
影响因子: 7.2
作者:
Alspach, Elise;Lussier, Danielle M.;Schreiber, Robert D.
通讯作者: Schreiber, Robert D.
DOI: 10.1016/j.cell.2018.10.014
发表时间: 2018-12-13
期刊: Cell
影响因子: 64.5
作者:
André P;Denis C;Soulas C;Bourbon-Caillet C;Lopez J;Arnoux T;Bléry M;Bonnafous C;Gauthier L;Morel A;Rossi B;Remark R;Breso V;Bonnet E;Habif G;Guia S;Lalanne AI;Hoffmann C;Lantz O;Fayette J;Boyer-Chammard A;Zerbib R;Dodion P;Ghadially H;Jure-Kunkel M;Morel Y;Herbst R;Narni-Mancinelli E;Cohen RB;Vivier E
通讯作者: Vivier E
DOI: 10.1038/mto.2016.11
发表时间: 2016
期刊: Molecular therapy oncolytics
影响因子: --
作者:
通讯作者: --